Semaglutide oral - Novo Nordisk
At a glance
- Drug Originator Novo Nordisk
- Drug Licenced by Merck Sharp & Dohme
- Drug Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
- USA Patent Applicants NOVO
- USA Patents 12
- NDAs 1
- International Patents 187
- Patent Applications 702
Table of Contents

Disclaimer